Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody
about
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancerIntegrin inhibitors as a therapeutic agent for ovarian cancerActivin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signalingSerous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.
P2860
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Expression of αV-integrins in ...... nist anti-αV-integrin antibody
@en
type
label
Expression of αV-integrins in ...... nist anti-αV-integrin antibody
@en
prefLabel
Expression of αV-integrins in ...... nist anti-αV-integrin antibody
@en
P2093
P2860
P1476
Expression of αV-integrins in ...... nist anti-αV-integrin antibody
@en
P2093
Alessandro D Santin
Deborah J Marshall
Emiliano Cocco
Federica Guzzo
Joyce Varughese
Karim El-Sahwi
Luisa Carrara
Marta Bellone
Paola Todeschini
Peter E Schwartz
P2860
P304
P356
10.1097/IGC.0B013E3182187324
P577
2011-08-01T00:00:00Z